Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest

Shui-er ZHENG1, #, Sang XIONG1, #, Feng LIN1, Guang-lei QIAO1, Tao FENG1, Zan SHEN1, Da-liu MIN1, Chun-ling ZHANG2, Yang YAO1, *

1Department of Oncology, Affiliated People’s 6th Hospital, Shanghai Jiao Tong University, Shanghai 200233, China; 2Department of Orthopaedics, Affiliated People’s 6th Hospital, Shanghai Jiao Tong University, Shanghai 200233, China

Aim: Pirarubicin (THP) is recently found to be effective in treating patients with advanced, relapsed or recurrent high-grade osteosarcoma. In this study, the effects of THP on the multidrug-resistant (MDR) osteosarcoma cells were assessed, and the underlying mechanisms for the disruption of cell cycle kinetics by THP were explored.

Methods: Human osteosarcoma cell line MG63 and human MDR osteosarcoma cell line MG63/DOX were tested. The cytotoxicity of drugs was examined using a cell proliferation assay with the Cell Counting Kit-8 (CCK-8). The distribution of cells across the cell cycle was determined with flow cytometry. The expression of cell cycle-regulated genes cyclin B1 and Cdc2 (CDK1), and the phosphorylated Cdc2 and Cdc25C was examined using Western blot analyses.

Results: MG63/DOX cells were highly resistant to doxorubicin (ADM) and gemcitabine (GEM), but were sensitive or lowly resistant to THP, methotrexate (MTX) and cisplatin (DDP). Treatment of MG63/DOX cells with THP (200–1000 ng/mL) inhibited the cell proliferation in time- and concentration-dependent manners. THP (50–500 ng/mL) induced MG63/DOX cell cycle arrest at the G2/M phase in time- and concentration-dependent manners. Furthermore, the treatment of MG63/DOX cells with THP (200–1000 ng/mL) downregulated cyclin B1 expression, and decreased the phosphorylated Cdc2 at Thr161. Conversely, the treatment increased the phosphorylated Cdc2 at Thr14/Tyr15 and Cdc25C at Ser216, which led to a decrease in Cdc2-cyclin B1 activity.

Conclusion: The cytotoxicity of THP to MG63/DOX cells may be in part due to its ability to arrest cell cycle progression at the G2/M phase, which supports the use of THP for managing patients with MDR osteosarcoma.

Keywords: osteosarcoma; multidrug-resistant; pirarubicin; doxorubicin; gemcitabine; methotrexate; cisplatin; cell cycle; G2/M arrest; cyclin B1; Cdc2; Cdc25C

Original Article

Introduction

Osteosarcoma is the most common malignant primary bone tumor in children, adolescents and young adults. Multiagent chemotherapy, commonly including doxorubicin (ADM), cisplatin (DDP) and high-dose methotrexate (MTX), has improved patient survival from 11% with surgical resection alone to 70% for localized disease. Unfortunately, the long-term survival for the remaining patients with recurrent disease is less than 20%[1-3]. Studies designed to identify novel active agents and implement strategies to overcome chemoresistance will likely be important for improving survival[1].

Recently, pirarubicin (THP), a novel anthracycline derivative of ADM, has been used clinically to treat tumors such as osteosarcoma, breast cancer, lymphoma and acute myeloid leukemia[4-7]. Moreover, THP has shown a greater antitumor activity[8-10] and lower cardiotoxicity[11] than ADM. This may be explained by the higher uptake of THP by tumor cells than ADM and its rapid distribution into the nucleus and subsequent incorporation into deoxyribonucleic acid (DNA)[12-14]. More recently, we found that through retrospective analysis, THP-based chemotherapy regimens were effective and safe as a salvage chemotherapy option for patients with lung metastases, refractory or recurrent high-grade osteosarcoma who previously received adjuvant chemotherapy with high dose-MTX–DDP–ADM–ifosfamide[15, 16]. However, the exact mechanisms by which THP exerts its antitumor effects are not understood. Although previous studies on THP...
have revealed that induction of cell cycle arrest at the G2 phase may contribute to its action in RPMI-8402 cells\[^7\], the molecular basis of the cell cycle arrest induced by THP remains unclear.

Considering this previous research, we speculated that THP might be a potential chemotherapeutic agent that can circumvent drug resistance in patients with osteosarcoma. However, few studies clearly define the effects of THP on cytotoxicity and multidrug-resistant (MDR) osteosarcoma cells. In this study, we investigated the in vitro cytotoxic response of the MDR osteosarcoma cell line MG63/DOX treated with THP and explored the underlying mechanisms THP utilizes to disrupt cell cycle kinetics.

### Materials and methods

#### Reagents

THP was obtained from Wan Le Pharma (Shenzhen, China); ADM and MTX, from Pfizer Pharma (New York, NY, USA); gemcitabine (GEM), from Lilly Pharma (Saint-Cloud, France); and DDP, from Hao Shen Pharma (Nanjing, China). Propidium iodide (PI) was purchased from Sigma Chemicals (St Louis, MO, USA). Cell Counting Kit-8 (CCK-8) was purchased from Dojindo Laboratories (Kumamoto, Japan).

#### Cell lines and cell culture

The human osteosarcoma parental cell line, MG63, was obtained from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). The human MDR osteosarcoma cell line MG63/DOX, which overexpresses P-glycoprotein (P-gp) and was selected in a step-wise manner by exposing drug-sensitive MG63 cells to increasing doses of ADM, was kindly provided by Dr Yoshio ODA (Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan)\[^8\]. The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Hyclone, Logan, UT, USA) supplemented with 10% heat-inactivated fetal calf serum (FCS; Sierra Qi, Hangzhou, China), 100 units/mL penicillin and 100 mg/mL streptomycin (Gibco, Grand Island, NY, USA) in a humidified atmosphere at 37 °C consisting of 5% CO\(_2\). Drugs were initially dissolved in phosphate-buffered saline (PBS) and then serially diluted in culture medium to the desired drug treatment concentrations.

#### Drug sensitivity and cytotoxicity assays

The effects of THP, ADM, MTX, DDP, and GEM on the proliferation of MG63/DOX and MG63 cells were measured using the CCK-8 colorimetric assay. Briefly, the cells were seeded in a 96-well microtiter plate at 5×10\(^3\) cells/well (100 μL). After 24 h of incubation with fresh medium, 10 μL of the various chemical dilutions at the indicated concentrations of each drug was added to the plates, and the cells were incubated for an additional 24, 48, and 72 h. At the end of drug treatment, 10 μL of CCK-8 was added to each well, and the cells were incubated for 4 h at 37 °C. Absorbance (A) was analyzed on a 96-well Opusys MR Microplate Reader (Thermo Labsystems, Beverly, MA, USA) at 450 nm. All experiments were tested in triplicate and repeated at least three times. The resistance factor (R factor) of multidrug-resistant cell line MG63/DOX for a particular drug is defined as the ratio of IC\(_{50}\) of MG63/DOX cell to IC\(_{50}\) of MG63 cell at 72 h (R<5×: low or no-resistance; R 5–15×: moderate-resistance; R>20×: high-resistance)\[^9\].

#### Cell cycle analysis

MG63/DOX cells were treated with THP for 24, 48, and 72 h at a drug concentration of 50, 200, and 500 ng/mL. Control cells were treated with solvent alone for the durations indicated above. Cell cycle was analyzed as previously described\[^20\]. The cells were trypsinized, washed twice with ice cold PBS, fixed in 70% ethanol and stained with propidium iodide (PI; 5 μg/mL PI in PBS containing 0.1% Triton X-100 and 0.2 mg/mL RNase A) in the dark for 30 min at 4°C. Finally, the cells were analyzed for cell cycle perturbation using a FACSCalibur flow cytometer (Becton-Dickinson, San Diego, CA, USA). Cell fluorescence was measured in duplicate at each time point, and all experiments were performed in triplicate.

#### Western blot analysis

Cells treated with THP at the indicated concentrations were harvested following 72 h of incubation. Western blotting was performed as described previously\[^21\]. Briefly, 30 μg of protein from whole-cell lysates was separated on a sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) apparatus and electrotransferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA, USA). After blocking with 5% (w/v), non-fat dry milk in Tris-buffered saline for 1 h at room temperature, membranes were incubated overnight at 4 °C with the previously described pretreated antibody diluent according to the one-step Western kit manufacturer’s instructions. Primary antibodies were incubated with a horseradish peroxidase antibody for 5 min at room temperature and then diluted (1:1000). The protein bands were visualized using a chemiluminescence imaging system (Bio-Rad, Hercules, CA, USA). All blots are representative of three independent experiments. Primary antibodies assayed were Cyclin B1, Cdc2, p-Cdc2 (Thr\(^14\)), p-Cdc2 (Tyr\(^15\)), and p-Cdc2 (Thr\(^61\)) antibodies (Cell Signaling Technology, Boston, MA, USA); Cdc25C and p-Cdc25C (Ser\(^116\)) antibodies (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA); and β-actin antibody (CoWin Biotech Co, Beijing, China).

#### Statistical analysis

Data are presented as the mean±SD. The Student’s t-test was used to analyze the difference between the mean values of the treatment and the control groups. Differences with a P value of less than 0.05 were considered statistically significant.

#### Results

##### Drug sensitivity

We investigated the effects of THP and chemotherapeutic agents commonly used for osteosarcoma treatment, including ADM, MTX, DDP, and GEM, on the proliferation of MG63/DOX MDR human osteosarcoma cells and their parental
MG63 cells using the CCK-8 colorimetric assay. As shown in Table 1, MG63/DOX cells exhibited high levels of resistance to ADM (R factor: 121.6) and GEM (R factor: 108.3) but little to no resistance to THP (R factor: 3.73), MTX (R factor: 4.16) and DDP (R factor: 0.91). These results indicate that MG63/DOX cells reveal have a classic MDR phenotype, which has been previously described[18]. Surprisingly, THP had similar inhibitory effects on cell proliferation in both resistant and parental osteosarcoma cells, indicating that MDR osteosarcoma cells are still sensitive to THP.

Table 1. Drug sensitivity of MG63 and MG63/DOX to the commonly used chemotherapeutic agents for osteosarcoma treatment. Mean±SD. n=3. *P>0.05, †P<0.05, ‡P<0.01 compared with MG63 cell group.

| Drug    | IC50 (μg/mL) MG63 | IC50 (μg/mL) MG63/DOX | R factor |
|---------|------------------|-----------------------|----------|
| THP     | 0.11±0.05        | 0.41±0.024^b          | 3.73     |
| ADM     | 0.15±0.09        | 18.24±7.72^c         | 121.6    |
| MTX     | 1.22±0.75        | 3.86±0.81^c          | 4.61     |
| DDP     | 3.83±0.52        | 3.48±0.24^a         | 0.91     |
| GEM     | 2.28±0.87        | 247.0±8.2^c         | 108.3    |

The resistance factor (R factor) of multidrug-resistant cell line MG63/DOX for a particular drug is defined as the ratio of IC50 of MG63/DOX cell to IC50 of MG63 cell at 72 h. R factor<5: low or no-resistance; R factor 5–15: moderate-resistance; R factor >20: high-resistance[19].

THP inhibited proliferation of MG63/DOX cells
The cytotoxic effects of THP on MG63/DOX cells were further measured with the CCK-8 colorimetric assay after the cells were exposed to various concentrations of THP for multiple durations. Cell growth was inhibited in a concentration- and time-dependent manner (Figure 1 and Table 2).

Table 2. Effect of THP on cell growth of MG63/DOX cells. *P>0.05, †P<0.01 compared with control.

| THP (ng/mL) | 0 | 24 | 48 | 72 |
|-------------|---|----|----|----|
| 0           | 0.128±0.031 | 0.203±0.024 | 0.329±0.027 | 0.633±0.056 |
| 200         | 0.100±0.010 | 0.195±0.013^ * | 0.269±0.028^c | 0.412±0.013^c |
| 500         | 0.123±0.023 | 0.186±0.007^c | 0.218±0.012 | 0.247±0.019^c |
| 1000        | 0.090±0.011 | 0.148±0.014^c | 0.139±0.010^c | 0.096±0.021^c |

concurrent reduction in the proportion of cells in G0/G1 and S phase was observed. These results demonstrate that THP induced a cycle arrest in MG63/DOX cells at G2/M phase in a time- and concentration-dependent manner.

THP reduced cyclin B1 expression and Cdc2 and Cdc25C activity
To elucidate the molecular basis for THP-induced cell cycle arrest at the G2/M phase, Cyclin B1, and Cdc2 protein expression was assayed by Western blotting. As shown in Figure 3, the results indicate that protein levels of cyclin B1 decreased after THP treatment in a time- and concentration-dependent manner but that the total protein levels of Cdc2 did not
change. The Cdc2-cyclin B1 complex was retained in an inactive state by the negative phosphorylation of the residues Thr14 and Tyr15 on Cdc2 phosphorylated by kinase Wee1 and Myt1, and Cdc2-cyclin B1 activity is increased by the phosphorylation of Cdc2 at Thr161. Therefore, we examined Cdc2 phosphorylation by Western blotting and found that while the protein expression level of Cdc2 was not altered, the phosphorylation of Cdc2 at Thr-14/Tyr-15 [p-Cdc2 (Thr 14/Tyr15)] was increased and the phosphorylation of Cdc2 at Thr-161 [p-Cdc2 (Thr161)] was decreased after THP treatment in a time- and concentration-dependent manner. These data suggest that reduced Cdc2-cyclinB1 activity by THP may account for the G2/M arrest in our model.

Cdc25C activates Cdc2 by removing inhibitory phosphate groups on Thr14 and Tyr15. Because Cdc2 phosphorylation at Thr14/Tyr15 was enhanced by THP, we further investigated the effect of THP on Cdc25C expression and phosphorylation at Ser216 by Western blotting. We found that the total protein expression levels of Cdc25C were not altered but that the phosphorylation of Cdc25C at Ser216 [p-Cdc25C (Ser 216)] was increased after THP treatment in a time- and concentration-dependent manner (Figure 3). These results suggest that decreased dephosphorylation by Cdc25C is partly responsible for Cdc2 inactivation.

Discussion
Currently, one of the greatest obstacles to improving the survival of patients with osteosarcoma is acquired clinical resistance to chemotherapeutic agents, primarily to the three most widely used agents in the treatment of osteosarcoma — ADM, MTX, and DDP[1, 22, 23]. Cancer cells can utilize a number of different mechanisms to become resistant to one or more chemotherapeutic drugs. Depending on the drug and cellular context, factors such as drug inactivation, drug target mutation, drug target upregulation and downregulation, decreased drug uptake, increased drug elimination and DNA damage repair have all been shown to contribute to both intrinsic and acquired resistant to chemotherapy[1]. ADM is one of the most effective agents for osteosarcoma treatment [1, 22, 23]. Although resistance to ADM in osteosarcoma is likely to be multifactorial, P-gp is thought to be the main resistance mechanism against this agent[1, 24]. Additionally, some retrospective studies[25, 26] have revealed that the overexpression of P-gp may be associated with poor prognosis. THP, a semisynthetic anthracycline glycoside, is a newer generation anthracycline anticancer agent that is reported to have a lower cardiotoxicity than ADM[21]. Changes in structure allow THP to be taken up by tumor cells approximately 170 times faster than ADM and increase the rates at which it distributes into the nucleus and

Figure 2. Effect of THP on cell cycle distribution of MG63/DOX cells. MG63/DOX cells were treated with the indicated concentrations (50, 200, and 500 ng/mL) of THP and harvested at 24, 48, or 72 h. DNA content was analyzed by flow cytometry using PI staining. THP induced MG63/DOX cells cycle arrest at the G2/M phase time and dose-dependently (reference Table 3). A representative profile is shown for each treatment.
Acta Pharmacologica Sinica

In conclusion, we have demonstrated an encouraging efficacy of THP against human MDR osteosarcoma cells in vitro. We also have found, for the first time, that THP could arrest the cell cycle at the G_{2}/M phase, which was partially associated with the downregulation of cyclin B1, p-Cdc2 (Thr^{161}), and the upregulation of p-Cdc2 (Thr^{14}), p-Cdc2 (Tyr^{15}), and p-Cdc25C (Ser^{216}). The alterations of cell cycle kinetics might contribute to a better understanding of the cytotoxicity induced by THP. These findings also provide a theoretical basis for its potential use in the management of patients with MDR osteosarcoma and suggest that further in vivo and prospective clinical studies are warranted.

Acknowledgements
We thank Dr Yoshio ODA for kindly providing the MG63/DOX cell line. This work was supported by grants from National Natural Science Foundation of China (Grant No 81001192 and 81172105) and Shanghai Health Bureau (Grant No 2011171).

Author contribution
Dr Yang YAO designed the research; Dr Shui-er ZHENG performed the research, wrote the paper, analyzed the data and designed the research; Dr Sang XIONG performed the research, analyzed the data, wrote the paper and designed the research; Dr Feng LIN designed the research; Dr Guang-
lei QIAO performed the research and analyzed the data; Dr Tao FENG performed the research; Dr Zan SHEN designed the research; Dr Da-liu MIN performed the research; and Dr Chun-ling ZHANG contributed new reagents.

References

1. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma current challenges and future directions. Expert Rev Anticancer Ther 2006; 6: 1075–85.
2. Hawkins DS, Arndt CA. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 2003; 98: 2447–56.
3. Chou AJ, Merola PR, Wexler LH, Gorlick RG, Vyas YM, Healey JH, et al. Treatment of osteosarcoma at first recurrence after contemporary therapy: the memorial sloan-kettering cancer center experience. Cancer 2005; 104: 2214–21.
4. Shinozaki T, Watanabe H, Yanagawa T, Shirakura K, Takagishi K. Pirarubicin-based versus doxorubicin-based osteosarcoma chemotherapy. Ann Pharmacother 2002; 36: 996–9.
5. Li JJ, Di GH, Tang LC, Yu KD, Hu Z, Liu GY, et al. Adjuvant therapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and 5-fluorouracil. Breast J 2011; 17: 657–60.
6. Kasahara S, Hara T, Tsurumi H, Goto N, Kitagawa J, Kanemura N, et al. Phase II study of the tetrahydropyranylatedrmiycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line therapy for elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2011; 52: 629–34.
7. Kudo K, Kojima S, Tabuchi K, Yabe H, Tawa A, Imaiuzumi M, et al. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with down syndrome and acute myeloid leukemia: the japanese Childhood AML Cooperative Study Group. J Clin Oncol 2007; 25: 5422–7.
8. Nagai K, Nagasawa K, Sadzuka Y, Tsujimoto M, Takara K, Ohashi N, et al. Relationships between the in vitro cytotoxicity and transport characteristics of pirarubicin and doxorubicin in M5076 ovarian sarcoma cells, and comparison with those in Ehrlich ascites carcinoma cells. Cancer Chemother Pharmacol 2002; 49: 244–50.
9. Umezawa H, Takahashi Y, Kinoshita M, Naganawa H, Masuda T, Ishizuka M, et al. Tetrahydropyranyldrmiycin derivatives of daunomycin and adriamycin. J Antibiot (Tokyo) 1979; 32: 1082–4.
10. Tsuruo T, Iida H, Tsukagoshi S, Harimaya K, Iwamoto Y, Tsuneyoshi M. Establishment of new multidrug-resistant human osteosarcoma cell lines. Oncol Rep 2000; 7: 859–66.
11. Qi WX, He AN, Tang LN, Shen Z, Yao Y. Evaluation of pirarubicin-cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute. Med Oncol 2011. doi: 10.1007/s12032-011-0211-y.
12. Oda Y, Matsumoto Y, Harimaya K, Iwamoto Y, Tsuneyoshi M. Establishment of new multidrug-resistant human osteosarcoma cell lines. Acta Pharmacol Sin 2011; 32: 1085–6.
13. Snow K, Judd W. Characterisation of adriamycin- and amsacrine-resistant human leukaemic T cell lines. Br J Cancer 1991; 63: 17–28.
14. Guo JM, Xiao BX, Liu Q, Zhang S, Liu DH, Gong ZH. Anticancer effect of aloe-emodin on cervical cancer cells involves G2/M arrest and induction of differentiation. Acta Pharmacol Sin 2007; 28: 1991–5.
15. Zheng SE, Yao Y, Dong Y, Lin F, Zhao H, Shen Z, et al. Down-regulation of ribosomal protein L7A in human osteosarcoma. J Cancer Res Clin Oncol 2009; 135: 1025–31.
16. Bacci G, Briccoli A, Ferrari S, Longhi A, Mercuri M, Capanna R, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli’s 4th protocol. Eur J Cancer 2001; 37: 2030–9.
17. Chi SN, Conklin LS, Qin J, Meyers PA, Huvos AG, Healey JH, et al. The patterns of relapse in osteosarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer 2004; 42: 46–51.
18. Caglierio E, Ferracini R, Morello E, Scotti K, Manara MC, Buracco P, et al. Reversal of multidrug-resistance using Valspodar (PSC 833) and doxorubicin in osteosarcoma. Oncol Rep 2004; 12: 1023–31.
19. Serra M, Scotti K, Reverter-Branchat G, Ferrari S, Manara MC, Benini S, et al. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol 2003; 21: 536–42.
20. Hornicek FJ, Gebhardt MC, Wolfe MW, Kharrazi FD, Takeshita H, Parekh SG, et al. P-glycoprotein levels predict poor outcome in patients with osteosarcoma. Clin Orthop 2000; 373: 11–7.
21. Kubota T, Furukawa T, Tanino H, Oura S, Murata H, Yuasa S, et al. Pirarubicin might partly circumvent the P-glycoprotein-mediated drug resistance of human breast cancer tissues. Anticancer Res 1998; 18: 967–72.
22. Kunimoto S, Miura K, Umezawa K. Cellular uptake and efflux and cytostatic activity of 4’-O-tetrahydropyranyldrmiycin in adriamycin-resistant and sensitive tumor cell lines. J Antibiot (Tokyo) 1984; 37: 1697–702.
23. Liu SY, Song SX, Lin L, Liu X. Molecular mechanism of cell apoptosis by paclitaxel and pirarubicin in a human osteosarcoma cell line. Chemotherapy 2010; 56: 101–7.
24. Maruyama T, Higuchi Y, Suzuki T, Qiu J, Yamamoto S, Shima H. Down-regulation of B-cell lymphoma 6 expression in a human osteosarcoma cell line. Cell Cycle 2007; 6: 1229–33.
25. Suryadinata R, Sadowski M, Sarcevic B. Control of cell cycle progression of a human osteosarcoma cell line using the antitumor drug pirarubicin. Mol Cell Biochem 2007; 303: 101–10.
26. Aphiwong VL, Suriyapa C, Chaiwong M, Duscharoen N, Phummipong C, et al. Evaluation of a novel antiangiogenic activity of pirarubicin in a human osteosarcoma cell line. Anti-cancer Res 2007; 27: 2797–803.
27. Maruyama T, Higuchi Y, Suzuki T, Qiu J, Yamamoto S, Shima H. Down-regulation of B-cell lymphoma 6 expression in a human osteosarcoma cell line. Cell Cycle 2007; 6: 1229–33.
28. Aphiwong VL, Suriyapa C, Chaiwong M, Duscharoen N, Phummipong C, et al. Evaluation of a novel antiangiogenic activity of pirarubicin in a human osteosarcoma cell line. Anti-cancer Res 2007; 27: 2797–803.
29. Maruyama T, Higuchi Y, Suzuki T, Qiu J, Yamamoto S, Shima H. Down-regulation of B-cell lymphoma 6 expression in a human osteosarcoma cell line. Cell Cycle 2007; 6: 1229–33.
30. Aphiwong VL, Suriyapa C, Chaiwong M, Duscharoen N, Phummipong C, et al. Evaluation of a novel antiangiogenic activity of pirarubicin in a human osteosarcoma cell line. Anti-cancer Res 2007; 27: 2797–803.
34 Dvory-Sobol H, Cohen-Noyman E, Kazanov D, Figer A, Birkenfeld S, Madar-Shapiro L, et al. Celecoxib leads to G$_2$/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner. Eur J Cancer 2006; 42: 422–6.
35 Doree M, Hunt T. From Cdc2 to Cdk1: when did the cell cycle kinase join its cyclin partner? J Cell Sci 2002; 115: 2461–4.
36 Taylor WR, Stark GR. Regulation of the G$_2$/M transition by p53. Oncogene 2001; 20: 1803–15.
37 Lopez-Girona A, Furnari B, Mondesert O, Russell P. Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein. Nature 1999; 397: 172–5.
38 Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 1997; 277: 1497–501.